Pfizer Banking On Exubera Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm acquires Sanofi-Aventis’ rights to the inhaled insulin product through a change-in-control clause.
You may also be interested in...
VCs Think Twice About Type 2 Diabetes Investments
Venture capitalists are reevaluating type 2 diabetes investments in light of daunting new regulatory hurdles and an economic climate that limits their ability to cash out of such companies in a timely fashion. But, say some VCs, truly innovative compounds may be worth the bigger R&D bills and longer time to exit given the dazzlingly large market at stake
VCs Think Twice About Type 2 Diabetes Investments
Venture capitalists are reevaluating type 2 diabetes investments in light of daunting new regulatory hurdles and an economic climate that limits their ability to cash out of such companies in a timely fashion. But, say some VCs, truly innovative compounds may be worth the bigger R&D bills and longer time to exit given the dazzlingly large market at stake
Sanofi's Diabetes Sales Force Increase Not Due To Threat From Exubera Or Levemir, Exec Says
Sanofi attributes its increased detailing focus on the diabetes market to changing prescribing trends, not increased competition.